Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

insulin U300 during the study period compared to the Lantus® group (45.3% vs. 59.7%; RR 0.76; 95% CI 0.66 to 0.87). New insulin U300 was well-tolerated in this study, with no differences in other adverse events observed from Lantus®.

The EDITION I abstract is titled: New Insulin Glargine Formulation: Glucose Control and Hypoglycemia in People with Type 2 Diabetes Using Basal and Mealtime Insulin (EDITION I) (Riddle, MC et al) [Abstract no. 43-LB]EDITION II Topline results of EDITION II are consistent with EDITION I findings. EDITION II demonstrated that investigational new insulin U300 achieved similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

EDITION II evaluated efficacy and safety of new insulin U300 in a type 2 diabetes population (811 patients) treated with basal insulin plus oral antidiabetic therapy. The full EDITION II results will be submitted for presentation at upcoming scientific meetings.

"There remains a substantial unmet need in people with diabetes taking oral medication or insulin as many of them do not reach their glycemic goals," said Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "With the investigational new insulin U300, we are striving to further enhance the clinical value of basal insulin, while building on the wealth of evidence of Lantus®, the world's most prescribed insulin."

About investigational new insulin U300Investigational new insulin U300 is a new formulation based on the glargine molecule, the biological entity of Lantus®, with its well established efficacy and safety profile. However, new insulin U300 has unique pharmacokinetic and pharmacodynamic profiles with studies demonstrating it has even flatter and more prolonged profiles than Lantus®.1,2 New insulin U300 also offers the benef
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Hologic, Inc. (NASDAQ: HOLX ... President and Chief Executive Officer, will preside over the ... the first day of Breast Cancer Awareness Month. In ... focused on the important benefits of Hologic,s 3D Mammography ... as clinically superior to traditional mammography. ...
(Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... OrthoWorx, the newly formed industry, community and education initiative to ... is working to connect the orthopedics capital of the world ... , In a September report, Warsaw, ... overview, analysis and blueprint for future industry and community growth, ...
... , , KNOXVILLE, Tenn., Dec. 15 Medical researchers ... their revolutionary new technology for a simple blood test to ... of its pre-clinical trials for the ColoMarker(TM) assay, EDP has ... of its use. Via an inexpensive blood test, ColoMarker(TM) ...
Cached Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3Researchers Announce Medical Breakthrough with Simple, Inexpensive Blood Test for Colon Cancer 2
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
(Date:10/1/2014)... N.C. A new genetic finding from Duke Medicine ... anxiety and depression might also be hard-wired to gain ... and heart disease. , An estimated 13 percent of ... genetic susceptibility, and knowing this could help them reduce ... diet, exercise and stress management. , "Genetic susceptibility, psychosocial ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Between 23 ... in the U.S., according to figures from the National ... Diseases Association (AARDA), and many of them have something ... of having undiagnosed celiac disease. Gluten Free Therapeutics, ... awareness of undiagnosed celiac disease by publishing a series ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... Study has Important Implications for Genetic Testing and Individualized Medicine ... long QT syndrome (LQTS) study published in ... understanding genetic testing,s role in diagnosing disease, according to the ... A pediatric cardiologist at Mayo Clinic, Dr. Ackerman directs Mayo,s ...
... , DALLAS, Nov. 5 Kimberly-Clark Corporation (NYSE: ... period under the Hart-Scott-Rodino Antitrust Improvements Act with respect ... (Nasdaq: IFLO). , Kimberly-Clark initiated a cash tender offer ... of I-Flow common stock. The tender offer will ...
... Even a slight elevation was linked to coronary artery calcification ... blood levels of phosphorus are associated with a higher risk ... link between phosphorus levels and coronary artery calcification (CAC) in ... long-term investigation of heart disease risk factors. CAC is an ...
... Lumenis® ... ophthalmic, surgical and aesthetic applications, announced today the initiation of a clinical study into ... will take place at the Tel Aviv Medical Center in Israel, under the leadership ... ...
... Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical ... product candidates principally for use in the hospital ... and nine months ended September 30, 2009. , ... the FDA for Cadence,s New Drug Application (NDA) ...
... could aid understanding of human diseases, scientists say , ... the domestic horse has been sequenced, an accomplishment that ... studies of human health, according to an international team ... makes it easier to understand all genomes, including our ...
Cached Medicine News:Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 2Health News:Research Findings Key for Understanding, Interpreting Genetic Testing for Long QT Syndrome 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 2Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 3Health News:Kimberly-Clark Corporation Announces Regulatory Clearance for Its Planned Acquisition of I-Flow Corporation 4Health News:Phosphorus Levels May Predict Heart Disease 2Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 2Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 3Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 4Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 5Health News:Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME) 6Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Health News:Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Health News:Complete Horse Genome Sequence Revealed 2
Anatomically designed 3 cervical foam collar...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
This model utilizes the Malibu Soft Cervical Collar with a Thoracic Extension....
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
Medicine Products: